Synthetic biology startups face a 'reckoning'.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39208098.
- Also identified by DOI 10.1126/science.ads7684.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three big firms falter, but startups find niches in pharma and other small-volume markets.